MEDFAC is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 4 July 2013, 1 establishment.

What is the address of MEDFAC?

The registered office of MEDFAC is located at Transportlaan 9, 3600 Genk.

Is MEDFAC still active?

Yes. According to the CBE (30 October 2026) MEDFAC is active, legal situation “Normale toestand”, started on 4 July 2013.

Is MEDFAC registered on Peppol?

Yes, MEDFAC is registered on the Peppol network with ID 0208:0536433259.

What is the enterprise number of MEDFAC?

The enterprise number of MEDFAC is BE0536433259.

When was MEDFAC founded?

MEDFAC was founded on 4 July 2013.

Who are the directors of MEDFAC?

According to the 2025 annual accounts, the directors of MEDFAC are: Spronken BV, Robert John Donaldson.

Is MEDFAC a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 July 2013; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did MEDFAC make in 2025?

MEDFAC posted a profit after taxes of € 207,786 in financial year 2025.

What is the revenue of MEDFAC?

As a small company, MEDFAC is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -11,357.

How many employees does MEDFAC have?

According to the 2025 annual accounts, MEDFAC has 0 full-time equivalents (FTE).

MEDFAC (Private Limited) - Genk - BE0536433259

Dossier MEDFAC, printed on 30 October 2026 from databakkes.be/en/0536433259/medfac. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MEDFAC from Genk, company number BE0536433259, closed financial year 2025 with a result of € 207,786 after tax. For that financial year MEDFAC recorded a gross margin of € -11,357 and equity of € 17.4 million. Compared with financial year 2024, the result moved from € 13.7 million to € 207,786. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Growing

€ 17.4 million

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 207,786

▼ 98% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.2 million

▲ 39% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 17.3 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 305,472

▼ 16% vs 2024

€ 62,579 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 2,993

▼ 75% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 25,454

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -33,720 Gross margin 2022: € -33,720 First fiscal year in the series	€ -46,093 Gross margin 2023: € -46,093 ▼ € 12,373 vs 2022 (€ -33,720) Unfavourable step	€ 9,963,187 Gross margin 2024: € 9,963,187 ▲ € 10 million vs 2023 (€ -46,093) Favourable step	€ -11,357 Gross margin 2025: € -11,357 ▼ € 10 million vs 2024 (€ 9,963,187) Unfavourable step	▼ € 10 million
Profit after taxes	€ 8,353 Profit after taxes 2022: € 8,353 First fiscal year in the series	€ 879,469 Profit after taxes 2023: € 879,469 ▲ € 871,116 vs 2022 (€ 8,353) Favourable step	€ 13,720,118 Profit after taxes 2024: € 13,720,118 ▲ € 12.8 million vs 2023 (€ 879,469) Favourable step	€ 207,786 Profit after taxes 2025: € 207,786 ▼ 98% vs 2024 (€ 13,720,118) Unfavourable step	▼ 98%
Equity	€ 2,546,981 Equity 2022: € 2,546,981 First fiscal year in the series	€ 3,426,450 Equity 2023: € 3,426,450 ▲ 35% vs 2022 (€ 2,546,981) Favourable step	€ 17,146,567 Equity 2024: € 17,146,567 ▲ € 13.7 million vs 2023 (€ 3,426,450) Favourable step	€ 17,354,353 Equity 2025: € 17,354,353 ▲ 1% vs 2024 (€ 17,146,567) Favourable step	▲ 1%
Total debts	€ 2,055,790 Total debts 2022: € 2,055,790 First fiscal year in the series	€ 3,046,754 Total debts 2023: € 3,046,754 ▲ 48% vs 2022 (€ 2,055,790) Unfavourable step	€ 404,944 Total debts 2024: € 404,944 ▼ 87% vs 2023 (€ 3,046,754) Favourable step	€ 361,876 Total debts 2025: € 361,876 ▼ 11% vs 2024 (€ 404,944) Favourable step	▼ 11%
Cash	€ 1,970,722 Cash 2022: € 1,970,722 First fiscal year in the series	€ 784,184 Cash 2023: € 784,184 ▼ 60% vs 2022 (€ 1,970,722) Unfavourable step	€ 860,725 Cash 2024: € 860,725 ▲ 10% vs 2023 (€ 784,184) Favourable step	€ 1,199,687 Cash 2025: € 1,199,687 ▲ 39% vs 2024 (€ 860,725) Favourable step	▲ 39%
Retained profit	€ 2,527,181 Retained profit 2022: € 2,527,181 First fiscal year in the series	€ 3,406,650 Retained profit 2023: € 3,406,650 ▲ 35% vs 2022 (€ 2,527,181) Favourable step	€ 17,126,767 Retained profit 2024: € 17,126,767 ▲ € 13.7 million vs 2023 (€ 3,406,650) Favourable step	€ 17,334,553 Retained profit 2025: € 17,334,553 ▲ 1% vs 2024 (€ 17,126,767) Favourable step	▲ 1%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 422,395 Bank debt 2023: € 422,395 Unchanged (€ 0) Unfavourable step	€ 365,264 Bank debt 2024: € 365,264 ▼ 14% vs 2023 (€ 422,395) Favourable step	€ 305,472 Bank debt 2025: € 305,472 ▼ 16% vs 2024 (€ 365,264) Favourable step	▼ 16%
Balance sheet total	€ 4,602,770 Balance sheet total 2022: € 4,602,770 First fiscal year in the series	€ 6,473,204 Balance sheet total 2023: € 6,473,204 ▲ 41% vs 2022 (€ 4,602,770) Unchanged	€ 17,551,511 Balance sheet total 2024: € 17,551,511 ▲ 171% vs 2023 (€ 6,473,204) Unchanged	€ 17,716,229 Balance sheet total 2025: € 17,716,229 ▲ 1% vs 2024 (€ 17,551,511) Unchanged	▲ 1%

Key figures of MEDFAC, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDFAC?

What happened at MEDFAC in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: profit of € 207,786 (▼ 98% vs 2024). filed late Source: NBB ↗
Jul 4, 2013 New establishment in Genk. KBO
Jul 4, 2013 Start of the company according to the CBE. KBO

In short

From € 8,353 profit in 2022 to € 207,786 profit in 2025.

Paid € 28,495 in corporate taxes since 2022.

Best year ever: 2024, with € 13.7 million profit.

Original PDFs at the National Bank ↗

Management

Spronken BV Robert John Donaldson

SPRONKEN ORTHOPEDIE

SPROTECH

MEDFAC

RUNLITE

Behind MEDFAC are Spronken BV and Robert John Donaldson. Spronken BV is also behind SPRONKEN ORTHOPEDIE, SPROTECH, QUALITY PRODUCTION, BELGO-INTERNATIONAL RESEARCH APPLICATIONS en DEVELOPMENT and SPRONKEN GROUP. Robert John Donaldson is also behind RUNLITE.

Directors

According to the 2025 annual accounts

Spronken BV

Director · represented by Maria Leonardina Spronken

Also active at: SPRONKEN ORTHOPEDIE, SPROTECH, QUALITY PRODUCTION, BELGO-INTERNATIONAL RESEARCH APPLICATIONS en DEVELOPMENT, SPRONKEN GROUP, ORTHO MEDICA, I'MMSPRO

Robert John Donaldson

Director

Also active at: RUNLITE

Establishments

Establishment units

Physical locations of this company

Registered office

Transportlaan 9

3600 Genk

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

SPRONKEN ORTHOPEDIE same network

€ 16.3 million revenue · 2025

QUALITY PRODUCTION same network

€ 1.8 million gross margin · 2025

SPRONKEN GROUP same network

€ 1 million gross margin · 2025

ORTHO MEDICA same network

€ -1,845 gross margin · 2025

SPRONKEN same network

€ 55,540 gross margin · 2025

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0536.433.259

VAT number

BE 0536.433.259

Registered office

Transportlaan 9, 3600 Genk

Names & denominations

MEDFAC

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

4 July 2013

Peppol

Active · Active since 15 Dec 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

MEDFAC

Financials

What happened to MEDFAC?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions